Brief report · 28 Aug 2023
Conference abstractPublished 5 Sep 2016
Designing next-generation drug development in precision medicine
Ioannina University, Greece
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Breakthrough next-generation sequencing (NGS) systems and computational network methods shape two main strategies in drugs-discovery design. First, based on spatiotemporal genomic clones evolution, novel targetable drugs can be discovered against genome-wide alterations. Primary tumor multiregional NGS analysis before and after neoadjuvant treatment can reveal both intratumor heterogeneity (ITH) and clonal evolution in response to this systemic treatment. Moreover, an innovative noninvasive method of repeated circulating cell-free tumor DNA (ctDNA) followed NGS (ctDNA-NGS) can reveal subclones of plasma levels at different time points. This monitoring of these patients can not only predict therapeutic resistance-based metastatic relapse but also can result in novel drugs development to prevent with high precision metastatic progression. Ultimately, comparison of ITH with ctDNA-NGS in future rationally designed clinical trial opens new horizons of comprehensive intrapatient heterogeneity (IPH) identification that could substantially improve tumor responsiveness and overall survival. Second, in a more distant future, approach understanding of noncoding genome variation and functionality along with exploitation of transcriptional networks, drive the future development of highly effective drugs disrupting deregulated cancer transcriptional biocircuits. Although this ENCODE projectâÂ?Â? based research direction reflects the pragmatic molecular interaction networks underlying critical biological processes; much more work and time is required for understanding how structural and functional genome changes are underlying therapeutic resistance and relapse. This speech is concentrated on these two main drugs-development strategies. The first one continues to be based on simple, single-gene linear transcription dogma agents. The second innovative highly complex transcriptional networks-based approach aims to the future discovery of drugs disrupting aberrant cancer transcriptional biocircuits.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Mini review · 27 Apr 2024
Embracing Phenotypic Drug Discovery for Next-generation Therapeutics
Editorial · 30 Jan 2025
Unleashing the Power of Next-Generation Sequencing (NGS) in Precision Medicine
Brief report · 29 May 2025
Next-Generation Drug Design Strategies For Future Therapeutics
Article · 1 Apr 2024
Designing Sustainable Polymeric Materials for Next-Generation Drug Delivery Systems
More from this journal
The newest in Medicinal Chemistry.
Brief report · 30 Jun 2026
Covalent Drugs in Medicinal Chemistry: Emerging Opportunities and Ongoing Challenges
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Dimitrios H Roukos”

